Loading cancer entity…
Loading cancer entity…
Clinical trials
183 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (33)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | unknown | Phase 1 / Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL |
| unknown |
| Phase 1 / Phase 2 |
| 30 |
| Huiqiang HuangOTHER |
| 1 |
| Mar 15, 2021 |
| clinicaltrials |
| NCT04480788 | CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study | unknown | Phase 1 | 9 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04008394 | Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies | unknown | Phase 1 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03383965 | CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas | unknown | Phase 1 | 20 | Immune Cell, Inc.INDUSTRY | 1 | Dec 27, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Apr 14, 2022source: clinicaltrials